e-Therapeutics plc (AIM:ETX), the drug discovery and development company, today announces its interim results for the six months ended 31 July 2013.
Highlights
(*Announced or updated today)
Lead cancer drug ETS2101 progressing in clinic
• Early findings reported from phase I trials in brain cancer and solid tumours
Help employers find you! Check out all the jobs and post your resume.
